WO2006044738A3 - Methods and compositions for treatment of free radical injury - Google Patents

Methods and compositions for treatment of free radical injury Download PDF

Info

Publication number
WO2006044738A3
WO2006044738A3 PCT/US2005/037157 US2005037157W WO2006044738A3 WO 2006044738 A3 WO2006044738 A3 WO 2006044738A3 US 2005037157 W US2005037157 W US 2005037157W WO 2006044738 A3 WO2006044738 A3 WO 2006044738A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellular
membrane
sealing
treatment
reestablished
Prior art date
Application number
PCT/US2005/037157
Other languages
French (fr)
Other versions
WO2006044738A2 (en
Inventor
Raphael C Lee
Original Assignee
Maroon Biotech Corp
Raphael C Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maroon Biotech Corp, Raphael C Lee filed Critical Maroon Biotech Corp
Priority to CA002584138A priority Critical patent/CA2584138A1/en
Priority to EP05805080A priority patent/EP1809272A4/en
Publication of WO2006044738A2 publication Critical patent/WO2006044738A2/en
Publication of WO2006044738A3 publication Critical patent/WO2006044738A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Therapeutic methods and compositions useful for the prevention and/or treatment of cellular membrane damage leading to or resulting from peroxidation of the cellular membrane and a breakdown of the barrier function of the cellular membrane. A therapeutic composition includes a combination of a membrane sealing sealing surfactant and a cofactor treatment consisting of an antioxidant and a cellular energy store. To affect this goal, the permeability of damaged cellular membranes is reestablished by the membrane sealing surfactant, effectively “sealing” the injured membranes. To facilitate rapid tissue recovery, cellular energy levels can be reestablished through addition of a cellular energy source such as, for example, MgCl2-ATP which, serves a further dual benefit of improving the cellular ion balance. Addition of an antioxidant eliminates the generation of Reactive Oxygen intermediates and enhances the metabolism of free radicals.
PCT/US2005/037157 2004-10-18 2005-10-18 Methods and compositions for treatment of free radical injury WO2006044738A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002584138A CA2584138A1 (en) 2004-10-18 2005-10-18 Methods and compositions for treatment of free radical injury
EP05805080A EP1809272A4 (en) 2004-10-18 2005-10-18 Methods and compositions for treatment of free radical injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61943204P 2004-10-18 2004-10-18
US60/619,432 2004-10-18

Publications (2)

Publication Number Publication Date
WO2006044738A2 WO2006044738A2 (en) 2006-04-27
WO2006044738A3 true WO2006044738A3 (en) 2007-05-03

Family

ID=36203593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/037157 WO2006044738A2 (en) 2004-10-18 2005-10-18 Methods and compositions for treatment of free radical injury

Country Status (4)

Country Link
US (1) US20060121016A1 (en)
EP (1) EP1809272A4 (en)
CA (1) CA2584138A1 (en)
WO (1) WO2006044738A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US8145317B2 (en) * 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US8131371B2 (en) * 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
KR20190067944A (en) 2004-01-22 2019-06-17 유니버시티 오브 마이애미 Topical co-enzyme q10 formulations and methodns of use
WO2008016640A2 (en) * 2006-08-01 2008-02-07 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
ES2755840T3 (en) 2007-03-22 2020-04-23 Berg Llc Topical formulations that have increased bioavailability
MX2009010778A (en) * 2007-04-05 2010-01-29 Phrixus Pharmaceuticals Inc Compositions and methods for the treatment of heart failure.
ES2594302T3 (en) 2007-12-17 2016-12-19 The Regents Of The University Of Michigan Compositions and procedures for treatment and prevention of skeletal muscle deficiencies
EP2271325A4 (en) 2008-04-11 2011-11-09 Cytotech Labs Llc Methods and use of inducing apoptosis in cancer cells
EP2350274B1 (en) * 2008-10-21 2019-01-23 The General Hospital Corporation Cell transplantation
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
WO2010080886A1 (en) 2009-01-09 2010-07-15 Recor Medical, Inc. Methods and apparatus for treatment of mitral valve in insufficiency
US11235062B2 (en) 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
KR20180056816A (en) 2009-05-11 2018-05-29 베르그 엘엘씨 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2601299B1 (en) 2010-08-06 2019-04-24 The General Hospital Corporation D/B/A Massachusetts General Hospital System and apparatus for cell treatment
EP3449856B1 (en) 2010-10-25 2023-06-28 Medtronic Ardian Luxembourg S.à.r.l. Device for evaluation and feedback of neuromodulation treatment
KR101933732B1 (en) 2011-04-04 2018-12-28 버그 엘엘씨 Methods of treating central nervous system tumors
MX351781B (en) 2011-06-17 2017-10-30 Berg Llc Inhalable pharmaceutical compositions.
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
WO2013134733A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg Sarl Biomarker sampling in the context of neuromodulation devices and associated systems and methods
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
MY178060A (en) 2014-03-25 2020-09-30 Genentech Inc Methods of preparing a poloxamer for use in cell culture medium
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
US9403941B2 (en) 2014-07-07 2016-08-02 Mast Therapeutics, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof
AU2018372826B2 (en) * 2017-11-22 2023-12-07 Bausch & Lomb Incorporated Ophthalmic viscoelastic compositions
US20220151958A1 (en) * 2020-11-17 2022-05-19 The Feinstein Institutes For Medical Research Methods and compositions for neuroprotection

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5659049A (en) * 1988-02-18 1997-08-19 Virginia Commonwealth University Antioxidant, antiphospholipase derivatives of ricinoleic acid
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
AU664112B2 (en) * 1992-07-31 1995-11-02 Merrell Dow Pharmaceuticals Inc. Synthetic peptide lung surfactants having covalently bonded antioxidants
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5691360A (en) * 1993-12-08 1997-11-25 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5648377A (en) * 1993-12-21 1997-07-15 Indena S.P.A. Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6489312B1 (en) * 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
NZ529526A (en) * 2001-04-24 2006-06-30 Purdue Research Foundation Method and compositions for treating mammalian nerve tissue injuries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAHN DE P. ET AL.: "Pharmacologic Neuroprotection in Experimental Spinal Cord Ischemia", JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, vol. 13, no. 1, pages 3 - 12, XP008092218 *
MARKS ET AL.: "Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection", THE FASEB JOURNAL, EXPRESS ARTICLE 10.1096/FJ.00-0547FJE, 20 February 2001 (2001-02-20), pages 1107 - 1109, XP003011132 *
ULUS A.T. ET AL.: "ATP-MgC12 utilization for spinal cord protection during experimental thoracic aortic occlusion", JOURNAL OF CARDIOVASCULAR SURGERY, vol. 40, no. 4, August 1999 (1999-08-01), pages 495 - 499, XP008092053 *

Also Published As

Publication number Publication date
EP1809272A4 (en) 2008-01-02
US20060121016A1 (en) 2006-06-08
CA2584138A1 (en) 2006-04-27
WO2006044738A2 (en) 2006-04-27
EP1809272A2 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
WO2006044738A3 (en) Methods and compositions for treatment of free radical injury
WO2006042238A3 (en) Methods of storing tissue matrices
WO2002060458A3 (en) Compositions and method of tissue superoxygenation
GB2407503B (en) Organ arrest, protection, preservation and recovery
MX2009011002A (en) Ischemia/reperfusion protection compositions and methods of using.
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
MX2009002415A (en) Inertization method for reducing the risk of fire in an enclosed area and device for carrying out said method.
WO2008089103A8 (en) Targeting ncca-atp channel for organ protection following ischemic episode
WO2004056315A3 (en) Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
NO20081846L (en) Biphenyl derivatives and their use in the treatment of hepatitis C
WO2009082753A3 (en) Asymmetrical rf drive for electrode of plasma chamber
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2009126877A3 (en) Methods and compositions for accelerating the generation of regulatory tcells ex vivo
WO2004080175A3 (en) Scaffold for cell growth and differentiation
WO2002058734A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
EA201290098A1 (en) METHOD OF OBTAINING POLYMERIC COMPOSITIONS BASED ON PROANTOCYANIDINE FOR PHARMACEUTICAL FORMS
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
WO2009038710A3 (en) Sunscreen compositions with low eye-sting and high spf
WO2007050348A3 (en) Potassium channel inhibitors
WO2005121138A3 (en) Heterotricyclic compounds for use as hcv inhibitors
WO2007070637A3 (en) Method of treating open wounds using hypochlorous acid
WO2007025166A3 (en) Devices, compositions and methods for the protection and repair of cells and tissues
WO2010039791A8 (en) Cellular elastomer compositions
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2584138

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005805080

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005805080

Country of ref document: EP